Free Trial

Viemed Healthcare (VMD) Competitors

Viemed Healthcare logo
$7.98 -0.04 (-0.50%)
(As of 12/20/2024 05:17 PM ET)

VMD vs. CDNA, PNTG, AVAH, AGL, CSTL, GRAL, FLGT, INNV, AUNA, and CELC

Should you be buying Viemed Healthcare stock or one of its competitors? The main competitors of Viemed Healthcare include CareDx (CDNA), The Pennant Group (PNTG), Aveanna Healthcare (AVAH), agilon health (AGL), Castle Biosciences (CSTL), Grail (GRAL), Fulgent Genetics (FLGT), InnovAge (INNV), Auna (AUNA), and Celcuity (CELC). These companies are all part of the "healthcare" industry.

Viemed Healthcare vs.

CareDx (NASDAQ:CDNA) and Viemed Healthcare (NASDAQ:VMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership, community ranking and dividends.

CareDx has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Comparatively, Viemed Healthcare has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.

Viemed Healthcare has a net margin of 4.87% compared to CareDx's net margin of -45.90%. Viemed Healthcare's return on equity of 8.72% beat CareDx's return on equity.

Company Net Margins Return on Equity Return on Assets
CareDx-45.90% -53.70% -30.42%
Viemed Healthcare 4.87%8.72%6.48%

74.2% of Viemed Healthcare shares are held by institutional investors. 4.9% of CareDx shares are held by company insiders. Comparatively, 20.0% of Viemed Healthcare shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

CareDx received 437 more outperform votes than Viemed Healthcare when rated by MarketBeat users. Likewise, 66.17% of users gave CareDx an outperform vote while only 42.86% of users gave Viemed Healthcare an outperform vote.

CompanyUnderperformOutperform
CareDxOutperform Votes
440
66.17%
Underperform Votes
225
33.83%
Viemed HealthcareOutperform Votes
3
42.86%
Underperform Votes
4
57.14%

Viemed Healthcare has lower revenue, but higher earnings than CareDx. CareDx is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CareDx$312.78M3.53-$190.28M-$2.70-7.63
Viemed Healthcare$214.30M1.45$10.24M$0.2729.56

In the previous week, CareDx had 9 more articles in the media than Viemed Healthcare. MarketBeat recorded 9 mentions for CareDx and 0 mentions for Viemed Healthcare. CareDx's average media sentiment score of 1.05 beat Viemed Healthcare's score of -0.55 indicating that CareDx is being referred to more favorably in the media.

Company Overall Sentiment
CareDx Positive
Viemed Healthcare Negative

CareDx currently has a consensus price target of $29.60, indicating a potential upside of 43.62%. Given CareDx's higher probable upside, analysts clearly believe CareDx is more favorable than Viemed Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CareDx
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43
Viemed Healthcare
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00

Summary

Viemed Healthcare beats CareDx on 10 of the 19 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VMD vs. The Competition

MetricViemed Healthcarehealth & allied services, not elsewhere classified IndustryMedical SectorNASDAQ Exchange
Market Cap$310.72M$1.91B$5.13B$9.07B
Dividend YieldN/A7.04%5.08%4.23%
P/E Ratio29.5615.5789.5817.17
Price / Sales1.453.171,116.12116.95
Price / Cash10.489.7742.8237.86
Price / Book2.703.044.774.78
Net Income$10.24M$69.56M$120.15M$225.60M
7 Day Performance-8.70%-1.73%-1.92%-1.23%
1 Month Performance-8.33%-2.76%11.47%3.36%
1 Year Performance1.27%-25.02%30.54%16.60%

Viemed Healthcare Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VMD
Viemed Healthcare
1.7209 of 5 stars
$7.98
-0.5%
N/A+3.6%$310.72M$214.30M29.56630Positive News
High Trading Volume
CDNA
CareDx
3.5915 of 5 stars
$22.54
-1.4%
$29.60
+31.3%
+90.5%$1.21B$280.32M-8.35740
PNTG
The Pennant Group
4.5689 of 5 stars
$29.73
+2.1%
$38.25
+28.7%
+100.7%$1.02B$544.89M42.815,791Analyst Forecast
News Coverage
AVAH
Aveanna Healthcare
0.9169 of 5 stars
$4.99
-0.8%
$4.27
-14.5%
+82.5%$964.19M$1.98B-14.7933,500Positive News
AGL
agilon health
2.3096 of 5 stars
$2.21
-1.3%
$4.28
+93.8%
-84.0%$910.56M$5.59B-2.381,117Gap Down
CSTL
Castle Biosciences
2.7304 of 5 stars
$28.71
-0.6%
$39.71
+38.3%
+34.4%$804.08M$311.88M144.35540Insider Trade
GRAL
Grail
0.4714 of 5 stars
$23.38
+5.5%
$16.00
-31.6%
N/A$785.59M$117.67M0.001,360Gap Down
FLGT
Fulgent Genetics
3.7083 of 5 stars
$19.71
+0.7%
$22.00
+11.6%
-35.9%$602.87M$277.76M-3.551,184News Coverage
Positive News
INNV
InnovAge
1.2858 of 5 stars
$4.45
+0.2%
$6.50
+46.1%
-25.4%$602.78M$786.51M-37.002,350Analyst Forecast
News Coverage
AUNA
Auna
3.2169 of 5 stars
$6.69
+2.8%
$13.40
+100.3%
N/A$494.51M$4.34B0.0014,958News Coverage
CELC
Celcuity
2.6129 of 5 stars
$12.26
-2.1%
$29.17
+137.9%
-13.6%$455.21MN/A-4.8040News Coverage
High Trading Volume

Related Companies and Tools


This page (NASDAQ:VMD) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners